1. Introduction {#sec1}
===============

Cancer is one of the most common malignancies worldwide; it is the leading cause of death in economically developed countries and the second leading cause of death in developing countries \[[@B1]\]. Approximately 12.7 million new cases of cancer and 7.6 million cancer-related deaths were reported in 2008 \[[@B2]\]. Despite the efforts exerted by many researchers to elucidate the mechanism of carcinogenesis, this process remains unclear to date. Environmental factors, diet, lifestyle, and smoking and drinking habits have been implicated in the development of cancer \[[@B3], [@B4]\]. Various epidemiological studies have revealed that inflammation-associated factors, such as interleukin- (IL-) 1, IL-6, IL-10, and tumor necrosis factor-*α*, are associated with cancer tumorigenesis \[[@B5]\].

Interleukin-17 (*IL-17*) is a proinflammatory cytokine that serves important functions in inflammation, autoimmune disorders, and cancer \[[@B6]\]. The IL-17 cytokine family consists of six members (IL-17A to IL-17F) and five receptors (IL-17RA to IL-17RD and SEF) \[[@B7], [@B8]\]. These cytokines are primarily produced from a subset of CD4+ effector cells known as Th17 cells \[[@B9], [@B10]\]. Clinical studies have shown increased IL-17 expression in malignant tumors \[[@B11]--[@B14]\].

Single nucleotide polymorphisms (SNPs) can alter gene functions and protein expression, which influence cell proliferation and increase cancer risk. The*IL-17A* rs2275913G\>A and*IL-17F* rs763780T\>C polymorphisms are the most common loci associated with*IL-17*activity and cancer risk. In 2009, Shibata et al. \[[@B15]\] conducted the first study and reported a positive relationship between gastric cancer and the*IL-17A* rs2275913G\>A polymorphism in a Japanese population. But no significant association was found between gastric cancer and polymorphisms of*IL-17F* rs763780 T\>C. Many epidemiological studies have focused on the association of the*IL-17A* rs2275913G\>A and*IL-17F* rs763780T\>C polymorphisms with cancer risk. However, the results of these studies are inconsistent. Therefore, we performed a meta-analysis to clarify the possible association of the*IL-17A* rs2275913G\>A and*IL-17F* rs763780T\>C polymorphisms with cancer risk.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

The PubMed, Embase, and Chinese National Knowledge Infrastructure databases were searched using the terms "cancer," "tumor," "interleukin-17," "IL-17," and "polymorphism," (last search was updated on January 20, 2014). The "Related Articles" option was also used in each research article to find potential relevant studies on the same topic. Only studies published in English or Chinese were included. The inclusion criteria in this meta-analysis were as follows: (a) researches that focused on population, (b) studies that evaluated the association of the*IL-17A* rs2275913G\>A and*IL-17F* rs763780T\>C polymorphisms with cancer risk, (c) case-controls studies, and (d) studies that contain available genotype frequency to estimate the odds ratio (OR) and 95% confidence intervals (CIs). The largest or the most recent publication was selected when some data were the same or overlapped.

2.2. Data Extraction {#sec2.2}
--------------------

Two investigators (Yu-Ming Niu and Hua Yuan) independently extracted the following information from each eligible publication: first author\'s name, publication year, country of origin, ethnicity of the individuals involved (categorized as Asian or Caucasian), source of controls, number of cases and controls, number of genotypes cases and controls, Hardy-Weinberg equilibrium (HWE) and minor allele frequency (MAF), and cancer category. Discrepancies were adjudicated by another author until consensus was achieved.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The strength of the association of the*IL-17A* rs2275913G\>A and*IL-17F* rs763780T\>C polymorphisms with cancer risk was assessed by calculating crude ORs with 95% CIs. Pooled ORs were conducted for minor allele versus major allele with five models. Stratified analyses were performed by ethnicity, study design, and cancer category. Heterogeneity was calculated based on the *I* ^2^ statistic with low, moderate, and high *I* ^2^ values of 25%, 50%, and 75%, respectively \[[@B16], [@B17]\]. When *I* ^2^ ≤ 50% (which indicated a lack of heterogeneity), the OR estimation of each model was calculated by using the fixed-effects model (Mantel-Haenszel method); otherwise, the random-effects model (DerSimonian and Laird method) was used. We generated forest plots sorted by publication year. Potential publication bias was estimated using Egger\'s linear regression test with funnel plot \[[@B18]\]. Sensitivity analyses were assessed by deleting each study to reflect the influence of individual datasets on the pooled ORs \[[@B19]\]. Statistical analysis was performed using STATA version 11.0 (Stata Corporation, College Station, TX, USA) with two-sided *P* values. *P* \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

A flow chart showing the study selection is presented in [Figure 1](#fig1){ref-type="fig"}. A total of 185 relevant studies were found with the research words and manual research. After careful review, 10 published case-control studies involving 4,516 cases and 5,645 controls met our inclusion criteria \[[@B15], [@B27]--[@B20]\]. We found 10 and 7 eligible studies with adequate genotype and research subjects according to*IL-17A* rs2275913G\>A and*IL-17F*rs763780T\>C polymorphism. All characteristics of the selected studies are summarized in [Table 1](#tab1){ref-type="table"}. Nine studies involved Asian populations (seven involved the Chinese population), and one study involved a Caucasian population. Diverse genotyping methods were used, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) \[[@B25], [@B21]\], TaqMan \[[@B26], [@B24], [@B20]\], polymerase chain reaction-sequence specific primers (PCR-SSCP) \[[@B15], [@B23]\], MassARRAY \[[@B27], [@B28]\], and SNaPshot SNP assay \[[@B22]\] methods in eligible publications. The genotypic distribution of controls in only two and three studies deviated from HWE in the*IL-17A* rs2275913G\>A and*IL-17F* rs763780T\>C polymorphisms, respectively.

3.2. Quantitative Synthesis {#sec3.2}
---------------------------

[Table 2](#tab2){ref-type="table"} shows the results of this meta-analysis and the heterogeneity test. The*IL-17A* rs2275913G\>A polymorphism showed significant associations with cancer risk in all populations (for A versus G: OR = 1.28, 95% CI: 1.16--1.41, *P* \< 0.001, *I* ^2^ = 61.1%; for GA versus GG: OR = 1.12, 95% CI: 1.02--1.23, *P* = 0.015, *I* ^2^ = 27.8%; for AA versus GG: OR = 1.71, 95% CI: 1.38--2.41, *P* \< 0.001, *I* ^2^ = 69.6%; for GA + AA versus GG: OR = 1.23, 95% CI: 1.13--1.34, *P* \< 0.001, *I* ^2^ = 6.4% ([Figure 2](#fig2){ref-type="fig"}); and for AA versus GG + GA: OR = 1.62, 95% CI: 1.27--2.07, *P* \< 0.001, *I* ^2^ = 81.4%). The succeeding stratified analysis according to HWE, ethnicity, and study design subgroup also presented that the*IL-17A* rs2275913G\>A polymorphism may be a strong risk factor in the development of cancer, especially gastric cancer, in the Chinese population.

Statistical analysis also indicated that the*IL-17F* rs763780T\>C polymorphisms were significantly associated with cancer risk, particularly gastric cancer (for C versus T: OR = 1.29, 95% CI: 1.14--1.46, *P* \< 0.001, *I* ^2^ = 0%; for TC versus TT: OR = 1.33, 95% CI: 1.13--1.55, *P* \< 0.001, *I* ^2^ = 21.6%; for CC versus TT: OR = 1.40, 95% CI: 1.04--1.88, *P* = 0.026, *I* ^2^ = 0%; for TC + CC versus TT: OR = 1.34, 95% CI: 1.16--1.55, *P* \< 0.001, *I* ^2^ = 16% ([Figure 3](#fig3){ref-type="fig"})).

3.3. Sensitivity Analysis {#sec3.3}
-------------------------

A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual data set on the pooled ORs, and the corresponding pooled ORs were not qualitatively altered. This indicated that the results about the association between*IL-17* gene polymorphisms and cancer risk were statistically robust (Figures [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}).

3.4. Publication Bias {#sec3.4}
---------------------

Funnel plot and Egger\'s test were performed to estimate the publication bias of literature. Publication bias was detected in the meta-analyses on the allele contrast, homozygote (AA versus GG), dominant, and recessive models of the*IL-17A* rs2275913G\>A polymorphism ([Figure 6](#fig6){ref-type="fig"} for GA + AA versus GG model), except for the GA versus GG model (*P* = 0.652). Stratified analyses were conducted only with the HWE and Chinese population, but the results were not substantially different. For the*IL-17F* rs763780T\>C polymorphism, the funnel plots did not show any asymmetrical evidence in all genetic models ([Figure 7](#fig7){ref-type="fig"}). The result was further supported by analysis using Egger\'s tests (*P* = 0.102 for C versus T; *P* = 0.185 for TC versus TT; *P* = 0.382 for CC versus TT; *P* = 0.114 for TC + CC versus TT ([Figure 7](#fig7){ref-type="fig"}); *P* = 0.792 for CC versus TT + TC).

4. Discussion {#sec4}
=============

Carcinogenesis is a multistep process that involves numerous factors, such as smoking, drinking, xenobiotics infections, nutrition deficiency, and host genetic factor. Cancer-related inflammation factors have been recently confirmed to increase the risk of developing malignant tumors. IL-17 is a relatively novel cytokine family that is connected with adaptive and innate immune systems. IL-17A and IL-17F are members of the IL-17 cytokine family that are responsible for the pathogenic activity of IL-17 cells, the lineage of CD4^+^ effector cells, and multiple proinflammatory mediators \[[@B29]\].

Genetic polymorphisms of the IL-17A and IL-17F cytokines could change the function and expression of cytokines, which influence the activity of ILs \[[@B12], [@B30], [@B31]\]. Several studies have revealed that*IL-17A* and*IL-17F* polymorphisms are associated with gastric cancer, breast cancer, and so on. However, the results of these studies are inconsistent.

In 2009, Shibata et al. \[[@B15]\] were the first to report that the AA homozygote was significantly correlated with the development of gastric cancer compared with the common homozygous genotype (GG) in a Japanese population (OR = 3.02, 95% CI: 1.86--4.91). One year later, Chen et al. \[[@B20]\] also found a positive relationship between gastric cancer and the*IL-17A* rs2275913G\>A polymorphism in a Chinese Han population with a drinking habit (for A versus G: OR = 1.37, 95% CI: 1.07--1.76). Similar results were reported by Arisawa et al. \[[@B23]\], Rafiei et al. \[[@B25]\], Zhang et al. \[[@B27]\], and Zhuet al. \[[@B28]\] in gastric cancer. Furthermore, the mutation of*IL-17A* rs2275913G\>A locus was also demonstrated as tumorigenic for bladder cancer \[[@B26]\], breast cancer \[[@B22]\], and cervical cancer \[[@B24]\]. However, another article detected no significant association between the*IL-17A*rs2275913G\>A polymorphism and gastric cancer risk \[[@B21]\].

Regarding the*IL-17F* rs763780T\>C polymorphism, Wu et al. \[[@B21]\] found that the CT and CC genotypes are associated with an increased risk of gastric cancer compared with the TT genotype (OR = 1.51, 95% CI: 1.22--1.87 for CT; OR = 1.61, 95% CI: 1.03--2.51 for CC). By contrast, Zhou et al. \[[@B26]\] showed that bladder cancer patients have significantly higher frequencies of T allele than controls. This result indicates that this T allele is significantly associated with bladder cancer (OR = 1.46, 95% CI: 1.07--2.00). Furthermore, other researches did not find any significant association between the*IL-17F* rs763780T\>C polymorphism and cancer risk \[[@B15], [@B27], [@B28], [@B24], [@B22]\].

To the best of our knowledge, this meta-analysis is the first to determine the association of*IL-17* polymorphisms with cancer risk. This study focused on two common*IL-17* polymorphisms, namely,*IL-17A* rs2275913G\>A (10 studies with 4,516 cases and 5,645 controls) and*IL-17F* rs763780T\>C (7 studies with 2,863 cases and 3,773 controls). Significant associations were found between the*IL-17A* rs2275913G\>A polymorphism and cancer risk in all five genotype models of total populations. Besides, we also detected some association between the*IL-17F* rs763780T\>C polymorphism and the risk of Asians (Chinese), population-based and hospital-based controls, and gastric cancer or other cancers in the subgroup analysis by HWE publications, ethnicity, control design, and cancer category. Interestingly, nine researches focused on Asian population; the results of our meta-analysis demonstrated that the*IL-17A* rs2275913G\>A polymorphism may be a stranger canner risk for Asian ethnicity (including Chinese). Moreover, the category of control design did not influence the results; not only the population-based but also the hospital-based controls all showed that significant association existed between*IL-17A* rs2275913G\>A polymorphism and cancer risk. In all selected publications, seven studies focused on gastric cancer and the results also indicated that*IL-17A* rs2275913G\>A polymorphism plays an important role during the development of gastric cancer. For*IL-17F* rs763780T\>C polymorphism, all selected studies were conducted in Asian population and significant association only was found in codominant model (CC versus TT) in total population. Furthermore, subgroup analyses revealed a significantly increased risk of gastric cancer with*IL-17F* rs763780T\>C polymorphism in four models. Another stratified analysis of population-based control also drew a consistent conclusion.

This meta-analysis has several limitations in result interpretation. First, each gene only has a moderate effect on cancer development. A combination of relative genotypes may be a higher risk factor than a single locus genotype. Linkage disequilibrium and haplotype analyses of the two polymorphisms were not conducted because of the lack of original data on the individual genotypes from the included studies. Second, certain publication biases existed until subgroup analyses were conducted. These deviations would influence the correctness and reliability of the results. Third, these results were based on unadjusted estimates, and the evaluations were limited without the effects of gene-gene and gene-environment interactions. Finally, most of the included studies had been conducted on Asians but not on Caucasians and Africans, and the association between ethnicity variation and cancer risk could not be explored deeply.

In conclusion, despite these limitations, the present meta-analysis demonstrates that the*IL-17A* rs2275913G\>A polymorphism is associated with cancer development. Furthermore, the*IL-17F* rs763780T\>C polymorphism may be a potential risk factor in the development of gastric cancer. In the future, large-scale, case-control, and well-designed studies must be conducted to validate the findings of our meta-analysis and to comprehensively understand the potential gene-gene and gene-environment interactions between*IL-17* polymorphisms and cancer risk.
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![Sensitivity analysis through deleting each study to reflect the influence of the individual dataset on the pooled ORs in GA + AA versus GG model of*IL-17A* rs2275913G\>A polymorphism.](MI2014-128490.004){#fig4}
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![Funnel plot analysis to detect publication bias for GA + AA versus GG model of*IL-17A* rs2275913G\>A polymorphism. Each point represents a separate study.](MI2014-128490.006){#fig6}

![Funnel plot analysis to detect publication bias for TC + CC versus TT model of*IL-17F* rs763780T\>C polymorphism. Each point represents a separate study.](MI2014-128490.007){#fig7}

###### 

Characteristics of case-control studies on IL-17A rs2275913G\>A and IL-17F rs763780 T\>C polymorphisms and cancer risk included in the meta-analysis.

  First author         Year   Country   Ethnicity   Source of controls    Case   Control   Genotype distribution   *P*for HWE^a^   MAF   Genotyping method   Cancer category                                              
  -------------------- ------ --------- ----------- --------------------- ------ --------- ----------------------- --------------- ----- ------------------- ----------------- ----- -------- ------ -------------------- -----------------
  Zhang \[[@B27]\]     2014   China     Asian       Population controls   260    512       110                     102             48    258                 187               67    \<0.01   0.31   MassARRAY            Gastric cancer
  Zhou \[[@B26]\]      2013   China     Asian       Hospital controls     301    446       79                      154             68    164                 204               78    0.29     0.40   TaqMan               Bladder cancer
  Zhu \[[@B28]\]       2014   China     Asian       Hospital controls     293    550       126                     122             45    273                 216               61    0.07     0.31   MassARRAY            Gastric cancer
  Rafiei \[[@B25]\]    2013   Iran      Caucasian   Healthy controls      161    171       56                      61              44    78                  72                21    0.49     0.33   PCR-RFLP             Gastric cancer
  Quan \[[@B24]\]      2012   China     Asian       Hospital controls     311    463       93                      142             76    168                 215               80    0.43     0.40   TaqMan               Cervical cancer
  Arisawa \[[@B23]\]   2012   Japan     Asian       Hospital controls     333    583       112                     137             84    218                 293               72    0.08     0.37   PCR-SSCP             Gastric cancer
  Wang \[[@B22]\]      2012   China     Asian       Population controls   491    501       165                     234             92    198                 245               58    0.17     0.36   SNaPshot SNP assay   Breast cancer
  Wu \[[@B21]\]        2010   China     Asian       Population controls   945    768       210                     485             250   193                 371               204   0.35     0.51   PCR-RFLP             Gastric cancer
  Chen \[[@B20]\]      2010   China     Asian       Population controls   1042   1090      300                     522             220   325                 541               224   0.97     0.45   TaqMan               Gastric cancer
  Shibata \[[@B15]\]   2009   Japan     Asian       Hospital controls     287    523       94                      124             69    175                 299               49    \<0.01   0.38   PCR-SSCP             Gastric cancer
                                                                                                                                                                                                                          
                                                                                           T/T                     T/C             C/C   T/T                 T/C               C/C                                         
                                                                                                                                                                                                                          
  Zhang \[[@B27]\]     2014   China     Asian       Population controls   260    512       209                     30              21    429                 53                30    \<0.01   0.11   MassARRAY            Gastric cancer
  Zhou \[[@B26]\]      2013   China     Asian       Hospital controls     301    446       240                     57              4     317                 124               5     0.06     0.15   TaqMan               Bladder cancer
  Zhu \[[@B28]\]       2014   China     Asian       Hospital controls     293    550       241                     35              17    463                 58                29    \<0.01   0.11   MassARRAY            Gastric cancer
  Quan \[[@B24]\]      2012   China     Asian       Hospital controls     311    462       222                     85              4     332                 126               5     0.06     0.15   TaqMan               Cervical cancer
  Wang \[[@B22]\]      2012   China     Asian       Population controls   491    502       382                     103             6     396                 99                7     0.77     0.11   SNaPshot SNP assay   Breast cancer
  Wu \[[@B21]\]        2010   China     Asian       Population controls   927    777       540                     332             55    527                 214               36    0.02     0.18   PCR-RFLP             Gastric cancer
  Shibata \[[@B15]\]   2009   Japan     Asian       Hospital controls     280    523       221                     55              4     419                 100               4     0.46     0.10   PCR-SSCP             Gastric cancer

^a^HWE in control.

MAF: minor allele frequency in control group.

###### 

Summary of ORs and 95% CI of IL-17A rs2275913G\>A and IL-17F rs763780T\>C polymorphisms and cancer risk.

              *N* ∗   A versus G   GA versus GG     AA versus GG   GA + AA versus GG   AA versus GG + GA                                                                                                                                                                                                 
  ----------- ------- ------------ ---------------- -------------- ------------------- ------------------- ---------------- ------------- ---------- ---------- ---------------- ------------- ---------- ---------- ---------------- ------------- ---------- ---------- ---------------- ------------- ----------
  Total       10      **1.28**     **1.16--1.41**   **\<0.001**    **61.1**            **1.12**            **1.02--1.23**   **0.015**     **27.8**   **1.71**   **1.38--2.14**   **\<0.001**   **69.6**   **1.23**   **1.13--1.34**   **\<0.001**   **6.4**    **1.62**   **1.27--2.07**   **\<0.001**   **81.4**
  HWE         8       **1.26**     **1.13--1.41**   **\<0.001**    **66.4**            **1.15**            **1.04--1.27**   **0.008**     **0**      **1.63**   **1.29--2.08**   **\<0.001**   **70**     **1.23**   **1.12--1.36**   **\<0.001**   **9.7**    **1.51**   **1.18--1.93**   **0.001**     **78.4**
  Ethnicity                                                                                                                                                                                                                                                                                               
   Asian      9       **1.25**     **1.14--1.37**   **\<0.001**    **56.5**            **1.12**            **1.02--1.23**   **0.019**     **35.6**   **1.65**   **1.32--2.05**   **\<0.001**   **68.6**   **1.22**   **1.12--1.33**   **\<0.001**   **4.4**    **1.55**   **1.21--1.99**   **0.001**     **81.6**
   China      7       **1.21**     **1.10--1.34**   **\<0.001**    **56.2**            **1.19**            **1.07--1.32**   **0.001**     **0**      **1.46**   **1.20--1.79**   **\<0.001**   **54.3**   **1.24**   **1.13--1.37**   **\<0.001**   **14.9**   **1.30**   **1.09--1.56**   **0.004**     **56.6**
  Design                                                                                                                                                                                                                                                                                                  
   PB         4       **1.16**     **1.01--1.32**   **0.031**      **63.3**            **1.14**            **1.01--1.29**   **0.041**     **0**      **1.34**   **1.02--1.76**   **0.033**     **65**     **1.18**   **1.05--1.32**   **0.006**     **1.1**    1.23       0.96--1.59       0.108         69.7
   HB         5       **1.35**     **1.23--1.48**   **\<0.001**    **0**               1.10                0.87--1.39       0.447         63.1       **1.97**   **1.64--2.37**   **\<0.001**   **0**      **1.28**   **1.12--1.46**   **\<0.001**   **11.8**   **1.87**   **1.38--2.52**   **\<0.001**   **69.2**
  Location                                                                                                                                                                                                                                                                                                
   Gastric    7       **1.26**     **1.11--1.44**   **\<0.001**    **70**              1.07                0.96--1.19       0.202         24.2       **1.70**   **1.26--2.30**   **0.001**     **77.8**   **1.18**   **1.06--1.30**   **0.001**     **0**      **1.67**   **1.18--2.36**   **0.004**     **87**
   Others     3       **1.33**     **1.19--1.49**   **\<0.001**    **0**               **1.27**            **1.05--1.53**   **0.013**     **6.6**    **1.81**   **1.43--2.29**   **\<0.001**   **0**      **1.39**   **1.18--1.65**   **\<0.001**   **0**      **1.56**   **1.27--1.91**   **\<0.001**   **0**
                                                                                                                                                                                                                                                                                                         
                      C versus T   TC versus TT     CC versus TT   TC + CC versus TT   CC versus TT + TC                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                         
  Total       7       1.09         0.91--1.30       0.347          64.6                1.06                0.84--1.34       0.629         70         **1.33**   **1.02--1.75**   **0.038**     **0**      1.08       0.87--1.35       0.486         70.3       1.26       0.96--1.65       0.098         0
  HWE         4       0.95         0.81--1.10       0.516          46.4                0.92                0.71--1.19       0.650         57.2       1.15       0.61--2.17       0.660         0          0.93       0.72--1.19       0.557         55.5       1.18       0.62--2.21       0.616         0
  Ethnicity                                                                                                                                                                                                                                                                                               
   China      6       1.08         0.88--1.33       0.439          70.4                1.06                0.81--1.39       0.676         74.7       **1.32**   **1.00--1.74**   **0.053**     **0**      1.08       0.84--1.39       0.555         75.1       1.24       0.94--1.63       0.130         0
  Design                                                                                                                                                                                                                                                                                                  
   PB         3       **1.29**     **1.13--1.41**   **\<0.001**    **32.4**            **1.34**            **1.14--1.57**   **\<0.001**   **43.4**   **1.40**   **1.01--1.96**   **0.045**     **0**      **1.34**   **1.05--1.57**   **\<0.001**   **45.8**   1.29       0.92--1.79       0.136         0
   HB         4       0.97         0.77--1.21       0.550          52.2                0.92                0.69--1.22       0.554         57.3       1.20       0.74--1.94       0.466         0          0.84       0.72--1.23       0.643         58.1       1.20       0.74--1.94       0.456         0
  Location                                                                                                                                                                                                                                                                                                
   Gastric    4       **1.29**     **1.14--1.46**   **\<0.001**    **0**               **1.33**            **1.13--1.55**   **\<0.001**   **21.6**   **1.40**   **1.04--1.88**   **0.026**     **0**      **1.34**   **1.16--1.55**   **\<0.001**   **16**     1.30       0.97--1.74       0.082         0
   Others     3       0.91         0.70--1.18       0.472          57.4                0.88                0.62--1.24       0.460         69.2       1.02       0.50--2.08       0.962         0          0.89       0.64--1.22       0.461         66.7       1.04       0.51--2.13       0.905         0

\*Numbers of comparisons.

^a^Test for heterogeneity.

[^1]: Academic Editor: Tânia Silvia Fröde
